Physician profile
Nadia Malik
NPI 1891834172
$7,057.79
in general payments reported to CMS, 2019-2025
42 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $268 · 2021: $981 · 2022: $1,421 · 2023: $1,597 · 2024: $1,140 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,043 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,043.30 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $942.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $813.87 | 2020-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $734.72 | 2021-2025 | |
| Lilly USA, LLC | $653.57 | 2020-2024 | Jardiance, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $644.41 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.31 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $308.60 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.43 | 2020-2024 | Xifaxan, Trulance, Cycloset |
| Merck Sharp & Dohme LLC | $224.36 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $198.46 | 2023-2025 | |
| Astellas Pharma US INC | $179.08 | 2022-2025 | Veozah |
| Intra-Sana Laboratories | $175.64 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Novartis Pharmaceuticals Corporation | $162.26 | 2021-2024 | |
| Corcept Therapeutics | $131.70 | 2024-2025 | Korlym |
| Biohaven Pharmaceutical Holding Company Ltd. | $123.32 | 2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $115.96 | 2022-2024 | Trintellix |
| Antares Pharma, INC. | $115.70 | 2021-2024 | Xyosted |
| Idorsia Pharmaceuticals US INC | $80.09 | 2023-2024 | Quviviq |
| Horizon Therapeutics Plc | $76.07 | 2021-2023 | Krystexxa |
| Ironwood Pharmaceuticals, INC | $75.72 | 2024 | |
| Genentech USA, INC. | $58.96 | 2020-2021 | |
| Axsome Therapeutics, INC. | $57.09 | 2023-2024 | Auvelity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.26 | 2022-2023 | Lifevest |
| Abbott Laboratories | $50.43 | 2022-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $39.91 | 2024 | Vyepti |
| Dexcom, INC. | $39.01 | 2023-2025 | Dexcom G6 Transmitter |
| Impulse Dynamics (USA) INC. | $35.92 | 2025 | Optimizer |
| Currax Pharmaceuticals LLC | $34.99 | 2019-2021 | |
| Esperion Therapeutics, INC. | $22.42 | 2023 | Nexletol |
| Xeris Pharmaceuticals, INC. | $21.52 | 2025 | Gvoke Hypopen |
| Althera Pharmaceuticals LLC | $21.08 | 2021 | |
| Ibsa Pharma INC. | $20.91 | 2025 | Flector, Licart, Tirosint |
| Exact Sciences Corporation | $20.10 | 2025 | The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $19.05 | 2024 | Ibsrela |
| Halozyme INC | $19.00 | 2023 | |
| Amarin Pharma, INC. | $17.40 | 2022 | |
| Avvisto Therapeutics, LLC | $17.16 | 2024 | Cycloset |
| Biohaven Pharmaceuticals, INC. | $16.69 | 2021 | |
| Agepha Pharma Fz LLC | $15.55 | 2024 | Lodoco |
| Glaxosmithkline, LLC. | $14.80 | 2023 | Shingrix, Trelegy Ellipta |
| Allergan, INC. | $14.80 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.